Skinvisible, Inc. (SKVI)

OTCMKTS · Delayed Price · Currency is USD
0.2000
-0.0299 (-13.01%)
Sep 12, 2025, 3:48 PM EDT
-13.01%
Market Cap1.08M
Revenue (ttm)20.00K
Net Income (ttm)-527.27K
Shares Out5.40M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume325
Average Volume1,592
Open0.0811
Previous Close0.2299
Day's Range0.0811 - 0.2000
52-Week Range0.0811 - 0.8498
Beta0.86
RSI51.41
Earnings DateNov 14, 2025

About Skinvisible

Skinvisible, Inc. focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women’s health, pain management, and other markets. The company’s flagship product includes Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It ... [Read more]

Founded 1998
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol SKVI
Full Company Profile

Financial Performance

In 2024, Skinvisible's revenue was $20,000, a change of 0.00% compared to the previous year's $20,000. Losses were -$565,654, -76.26% less than in 2023.

Financial Statements

News

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and...

8 months ago - Accesswire

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® dr...

8 months ago - Accesswire

Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development

Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / Oct...

1 year ago - Accesswire

Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Ph...

1 year ago - Accesswire

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an inn...

1 year ago - Accesswire

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...

1 year ago - Accesswire

Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...

3 years ago - Accesswire